Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 56 clinical trials
Dasatinib Holiday for Improved Tolerability

Inhibitors (2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

potassium
leukemia
dasatinib
imatinib
nilotinib
  • 11 views
  • 25 Jan, 2021
  • 80 locations
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete

leukemia
remission
dasatinib
  • 7 views
  • 08 Nov, 2020
  • 1 location
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia

  • 38 views
  • 25 Jan, 2021
  • 432 locations
Treatment Modification Based on Early Assessment of CML Patients

TKI (as nilotinib, dasatinib). The investigators will follow on lab and clinical outcomes.

philadelphia chromosome
philadelphia chromosome positive chronic myelogenous leukemia
leukemia
tyrosine
kinase inhibitor
  • 5 views
  • 08 Nov, 2020
  • 1 location
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib. For all options the treatment duration is for a minimum of 12 months and will be

  • 11 views
  • 24 Jan, 2021
  • 24 locations
A Study in Patients With Chronic Leukemia Where Previous Therapy Failed and Who Will be Treated With Ponatinib as Second Line Therapy (PONS).

This study will include patients suffering from chronic myeloid leukemia (CP-CML), who were treated with tyrosine kinase inhibitor (TKI, a substance that blocks the action of enzymes) in a previous therapy but which has not been effective. Patients will be treated with Ponatinib 30 mg in in this study. The …

  • 0 views
  • 23 Jan, 2021
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

The purpose of this multicenter randomized study is to compare efficacy and safety of dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic phase (CP) chronic

cytarabine
kinase inhibitor
dasatinib
dasatinib 100 mg
leukemia
  • 8 views
  • 23 Jan, 2021
  • 4 locations
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.

nilotinib
dasatinib
tyrosine
imatinib
  • 106 views
  • 16 Jan, 2021
  • 18 locations
Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

This study will enroll CML patients who have failed a first TKI stopping attempt. After failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment for another 2

  • 18 views
  • 22 Jan, 2021
  • 22 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

The overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Primary Therapeutic Objectives: To …

methotrexate
blinatumomab
doxorubicin
vorinostat
residual tumor
  • 230 views
  • 17 Jan, 2021
  • 6 locations